|
| Date | 3/28/2025 12:03:39 PM |
Azacitidine belongs to anti-cancer therapy of Oncology Division. Azashine is indicated for treatment of patients with the myelodysplastic syndrome subtypes: Refractory anemia or refractory anemia with ringed sideroblasts, Refractory anemia with excess blasts, in transformation, and chronic myelomonocytic leukemia.
To know more call us
|